MX2021002993A - Métodos para el tratamiento de la hipertrofia del músculo masetero. - Google Patents

Métodos para el tratamiento de la hipertrofia del músculo masetero.

Info

Publication number
MX2021002993A
MX2021002993A MX2021002993A MX2021002993A MX2021002993A MX 2021002993 A MX2021002993 A MX 2021002993A MX 2021002993 A MX2021002993 A MX 2021002993A MX 2021002993 A MX2021002993 A MX 2021002993A MX 2021002993 A MX2021002993 A MX 2021002993A
Authority
MX
Mexico
Prior art keywords
methods
masseter muscle
hypertrophy
treatment
kits
Prior art date
Application number
MX2021002993A
Other languages
English (en)
Spanish (es)
Inventor
Christine Somogyi
Elisabeth Lee
Beta Bowen
John D Rogers
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2021002993A publication Critical patent/MX2021002993A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Traffic Control Systems (AREA)
MX2021002993A 2018-09-13 2019-09-12 Métodos para el tratamiento de la hipertrofia del músculo masetero. MX2021002993A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731064P 2018-09-13 2018-09-13
PCT/US2019/050910 WO2020056204A1 (en) 2018-09-13 2019-09-12 Methods for treatment of masseter muscle hypertrophy

Publications (1)

Publication Number Publication Date
MX2021002993A true MX2021002993A (es) 2021-08-11

Family

ID=68069888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002993A MX2021002993A (es) 2018-09-13 2019-09-12 Métodos para el tratamiento de la hipertrofia del músculo masetero.

Country Status (11)

Country Link
US (3) US20200085923A1 (https=)
EP (1) EP3849585A1 (https=)
JP (2) JP2022500417A (https=)
KR (1) KR20210057106A (https=)
CN (1) CN112955166A (https=)
AU (2) AU2019337656A1 (https=)
BR (1) BR112021004776A2 (https=)
CA (1) CA3112227A1 (https=)
MX (1) MX2021002993A (https=)
TW (2) TW202434280A (https=)
WO (1) WO2020056204A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230152107A (ko) * 2021-02-26 2023-11-02 이온 바이오파마, 인크. 두통을 치료하는 데 사용하기 위한 신경독소 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
CA2501856A1 (en) * 2002-10-15 2004-04-29 Allergan, Inc. Botulinum toxin dental therapies and procedures
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
WO2006073410A1 (en) * 2005-01-03 2006-07-13 Botulinum Toxin Research Associates, Inc. Compositions, methods and devices for preparing less painful botulinum toxin formulations
WO2009139739A1 (en) * 2006-02-14 2009-11-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
RU2535115C1 (ru) * 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
EP3368071B1 (en) * 2015-10-29 2022-01-26 ReVance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect

Also Published As

Publication number Publication date
WO2020056204A1 (en) 2020-03-19
KR20210057106A (ko) 2021-05-20
EP3849585A1 (en) 2021-07-21
JP2024177185A (ja) 2024-12-19
TW202023606A (zh) 2020-07-01
AU2025226702A1 (en) 2025-09-25
TWI835858B (zh) 2024-03-21
US20200085923A1 (en) 2020-03-19
US20230080740A1 (en) 2023-03-16
BR112021004776A2 (pt) 2021-11-09
JP2022500417A (ja) 2022-01-04
TW202434280A (zh) 2024-09-01
AU2019337656A1 (en) 2021-05-06
CN112955166A (zh) 2021-06-11
CA3112227A1 (en) 2020-03-19
US20230083250A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
MX2022001607A (es) Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola.
PH12020551427A1 (en) Epinephrine spray formulations
CL2020002914A1 (es) Métodos y composiciones para tratar el cáncer
SA520411910B1 (ar) تركيبات وطرق لعلاج اضطرابات مناعية باستخدام سلالات بكتيرية من المكورات اللبنية المعدلة للمناعة
AR106800A1 (es) Composiciones que comprenden cepas bacterianas
MX384240B (es) Bacterias probioticas recombinantes.
AR093386A1 (es) Composicion para tratar la diabetes o la diabesidad que comprende un analogo de oxintomodulina y metodo de tratamiento
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
MX2018002067A (es) Manejo con tetraciclina de dermatosis asociada con inhibidor de egfr.
MX2021006463A (es) Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3.
CL2021003045A1 (es) Tratamiento de la disfunción sistólica
MX381544B (es) Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.
MX2020004411A (es) Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren.
CO2019014592A2 (es) Neurotoxina botulínica para el tratamiento de trastornos asociados a la hiperactividad de melanocito y/o exceso de melanina
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
MX2018014621A (es) Composicion biopesticida para uso en la prevencion o para minimizar la enfermedad de la planta.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2021002993A (es) Métodos para el tratamiento de la hipertrofia del músculo masetero.
MX2021011263A (es) Uso de moduladores del receptor gabaa para el tratamiento del dolor.
MX2023009895A (es) Compuestos y composiciones para tratar la fibrosis.
MX2020000625A (es) Metodos para tratar trastornos microvasculares autoinmunes.
WO2019040104A3 (en) COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES
BRPI0514836A (pt) uso de toxina botulìnica para tratamento de uma deformidade da nádega
MX2022002853A (es) Composiciones de neurotoxina para uso en el tratamiento de la gastroparesia.